Last reviewed · How we verify
NCT07374510
Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine
Phase 1 trial testing high-dose Group ACYW135X Meningococcal Conjugate Vaccine in Meningococcal Meningitis in 150 participants. Not yet recruiting.
10 September 2026
Quick facts
| Lead sponsor | Sinovac Life Sciences Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 150 |
| Start date | 21 January 2026 |
| Primary completion | 10 September 2026 |
| Estimated completion | 30 November 2026 |
Drugs / interventions tested
- high-dose Group ACYW135X Meningococcal Conjugate Vaccine — full drug profile →
- medium-dose Group ACYW135X Meningococcal Conjugate Vaccine — full drug profile →
- low-dose Group ACYW135X Meningococcal Conjugate Vaccine — full drug profile →
- Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) — full drug profile →
- Placebo
Conditions studied
- Meningococcal Meningitis — all drugs for Meningococcal Meningitis →
Sponsor
Sinovac Life Sciences Co., Ltd. — full company profile →
Who can join
Adults 2 to 59, any sex, with Meningococcal Meningitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial adopts an open-label design combined with randomized, blinded, placebo-controlled and active-controlled design. The purpose of this trial is to evaluate the safety and immunogenicity of a Group ACYW135X Meningococcal Conjugate Vaccine. This study is planned to enroll 150 participants in total, with healthy individuals aged 2 to 59 years as participants. Among them, participants aged 18 to 59 years and 7 to 17 years will be assigned to the open-label design arm, while participants aged 4 to 6 years will be assigned to the randomized, blinded, placebo-controlled design arms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07374510
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Meningococcal Meningitis
Currently open trials in the same condition.
- NCT06700148 — A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds · Phase 3 · active not recruiting
Other Sinovac Life Sciences Co., Ltd. trials
Trials by the same sponsor.
- NCT06967272 — PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) · Phase 2 · recruiting
- NCT06617715 — Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine · Phase 3 · recruiting
- NCT06550830 — Clinical Trial of PCV24 in Children Aged 2-17 Years · Phase 1 · completed
- NCT06474377 — Clinical Trial of PCV24 in Adults · Phase 1 · completed
- NCT06950645 — The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07374510 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sinovac Life Sciences Co., Ltd.
- Last refreshed: 28 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07374510.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing